Thrombocytopenia in Patients With Atrial Fibrillation on Oral Anticoagulation Undergoing Percutaneous Coronary Intervention

      Thrombocytopenia is often regarded as a risk factor for bleeding complications in patients undergoing percutaneous coronary intervention (PCI). The risk of mild to moderate baseline and acquired thrombocytopenia on bleeding and thrombotic or thromboembolic complications in patients with atrial fibrillation on oral anticoagulation therapy undergoing PCI, however, remains largely unknown. Management of Patients With Atrial Fibrillation undergoing Coronary Artery Stenting is a multicenter European prospective registry enrolling patients with atrial fibrillation undergoing PCI. We assessed the rate of bleeding complications as defined by Bleeding Academic Research Consortium and a composite of major adverse cardiac and cerebrovascular events (MACCE) including all-cause mortality, myocardial infarction, transient ischemic attack or stroke, stent thrombosis, systemic arterial embolism, or revascularization; and a composite of any harmful event (Bleeding Academic Research Consortium and MACCE) at 12-month follow-up in 861 consecutive patients undergoing PCI. Patients were divided into those with mild to moderate baseline thrombocytopenia (platelet count <150 × 109/L; n = 99) and control group (platelet count >150 × 109/L; n = 762). At hospital discharge, thrombocytopenia had no effect on prescribed antithrombotic treatment, and triple therapy (vitamin K antagonist + aspirin + clopidogrel) was the most common combination in both patient groups (69% vs 73%, p = 0.40). No differences in all-cause mortality (12% vs 11%, p = 0.79), MACCE (23% vs 22%, p = 0.87), or bleeding complications (23% vs 19%, p = 0.26) were detected. Acquired in-hospital thrombocytopenia occurred in 9.7% of patients, and it was associated with similar risk of adverse outcomes compared with control group. In conclusion, mild to moderate baseline thrombocytopenia does not seem to have a clinically significant effect on bleeding or thrombotic or thromboembolic complications after PCI in these frail patients receiving multiple antithrombotic drugs.
      To read this article in full you will need to make a payment

      Purchase one-time access:

      Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online access
      One-time access price info
      • For academic or personal research use, select 'Academic and Personal'
      • For corporate R&D use, select 'Corporate R&D Professionals'


      Subscribe to American Journal of Cardiology
      Already a print subscriber? Claim online access
      Already an online subscriber? Sign in
      Institutional Access: Sign in to ScienceDirect


        • Lip G.Y.H.
        • Huber K.
        • Andreotti F.
        • Arnesen H.
        • Airaksinen J.K.
        • Cuisset T.
        • Kirchhof P.
        • Marín F.
        Antithrombotic management of atrial fibrillation patients presenting with acute coronary syndrome and/or undergoing coronary stenting: executive summary—a consensus document of the European Society of Cardiology Working Group on Thrombosis, endorsed by the European Heart Rhythm Association (EHRA) and the European Association of Percutaneous Cardiovascular Interventions (EAPCI).
        Eur Heart J. 2010; 31: 1311-1318
        • Eikelboom J.W.
        • Anand S.S.
        • Mehta S.R.
        • Weitz J.I.
        • Yi C.
        • Yusuf S.
        Prognostic significance of thrombocytopenia during hirudin and heparin therapy in acute coronary syndrome without ST elevation: organization to assess strategies for ischemic syndromes (OASIS-2) study.
        Circulation. 2001; 103: 643-650
        • Nikolsky E.
        • Sadeghi H.M.
        • Effron M.B.
        • Mehran R.
        • Lansky A.J.
        • Na Y.
        • Cox D.A.
        • Garcia E.
        • Tcheng J.E.
        • Griffin J.J.
        • Stuckey T.D.
        • Turco M.
        • Carroll J.D.
        • Grines C.L.
        • Stone G.W.
        Impact of in-hospital acquired thrombocytopenia in patients undergoing primary angioplasty for acute myocardial infarction.
        Am J Cardiol. 2005; 96: 474-481
        • Yeh R.W.
        • Wiviott S.D.
        • Giugliano R.P.
        • Morrow D.A.
        • Shui A.
        • Qin J.
        • Scirica B.
        • Bradner J.E.
        • Jang I.
        • Gibson C.M.
        • Antman E.M.
        Effect of thrombocytopenia on outcomes following treatment with either enoxaparin or unfractionated heparin in patients presenting with acute coronary syndromes.
        Am J Cardiol. 2007; 100: 1734-1738
        • Overgaard C.B.
        • Ivanov J.
        • Seidelin P.H.
        • Todorov M.
        • Mackie K.
        • Dzavik V.
        Thrombocytopenia at baseline is a predictor of inhospital mortality in patients undergoing percutaneous coronary intervention.
        Am Heart J. 2008; 156: 120-124
        • Oliveira G.B.
        • Crespo E.M.
        • Becker R.C.
        • Honeycutt E.F.
        • Abrams C.S.
        • Anstrom K.J.
        • Berger P.B.
        • Davidson-Ray L.D.
        • Eisenstein E.L.
        • Kleiman N.S.
        • Moliterno D.J.
        • Moll S.
        • Rice L.
        • Rodgers J.E.
        • Steinhubl S.R.
        • Tapson V.F.
        • Ohman E.M.
        • Granger C.B.
        Incidence and prognostic significance of thrombocytopenia in patients treated with prolonged heparin therapy.
        Arch Intern Med. 2008; 168: 94-102
        • Wang T.Y.
        • Ou F.
        • Roe M.T.
        • Harrington R.A.
        • Ohman E.M.
        • Gibler W.B.
        • Peterson E.D.
        Incidence and prognostic significance of thrombocytopenia developed during acute coronary syndrome in contemporary clinical practice.
        Circulation. 2009; 119: 2454-2462
        • De Labriolle A.
        • Bonello L.
        • Lemesle G.
        • Roy P.
        • Steinberg D.H.
        • Xue Z.
        • Suddath W.O.
        • Satler L.F.
        • Kent K.M.
        • Pichard A.D.
        • Lindsay J.
        • Waksman R.
        Decline in platelet count in patients treated by percutaneous coronary intervention: definition, incidence, prognostic importance, and predictive factors.
        Eur Heart J. 2010; 31: 1079-1087
        • Lahtela H.
        • Rubboli A.
        • Schlitt A.
        • Karjalainen P.P.
        • Niemelä M.
        • Vikman S.
        • Puurunen M.
        • Weber M.
        • Valencia J.
        • Biancari F.
        • Lip G.Y.H.
        • Airaksinen K.E.J.
        • AFCAS (Management of patients with Atrial Fibrillation undergoing Coronary Artery Stenting), study group
        Heparin bridging vs. uninterrupted oral anticoagulation in patients with atrial fibrillation undergoing coronary artery stenting; – results from the AFCAS registry.
        Circ J. 2012; 76: 1363-1368
        • Kiviniemi T.
        • Karjalainen P.
        • Pietilä M.
        • Ylitalo A.
        • Niemelä M.
        • Vikman S.
        • Puurunen M.
        • Biancari F.
        • Airaksinen K.E.J.
        Comparison of additional versus no additional heparin during therapeutic oral anticoagulation in patients undergoing percutaneous coronary intervention.
        Am J Cardiol. 2012; 110: 30-35
        • Cutlip D.E.
        • Windecker S.
        • Mehran R.
        • Boam A.
        • Cohen D.J.
        • van Es G.
        • Gabriel Steg P.
        • Morel M.
        • Mauri L.
        • Vranckx P.
        • McFadden E.
        • Lansky A.
        • Hamon M.
        • Krucoff M.W.
        • Serruys P.W.
        • Academic Research Consortium
        Clinical end points in coronary stent trials.
        Circulation. 2007; 115: 2344-2351
        • Mehran R.
        • Rao S.V.
        • Bhatt D.L.
        • Gibson C.M.
        • Caixeta A.
        • Eikelboom J.
        • Kaul S.
        • Wiviott S.D.
        • Menon V.
        • Nikolsky E.
        • Serebruany V.
        • Valgimigli M.
        • Vranckx P.
        • Taggart D.
        • Sabik J.F.
        • Cutlip D.E.
        • Krucoff M.W.
        • Ohman E.M.
        • Steg P.G.
        • White H.
        Standardized bleeding definitions for cardiovascular clinical trials: a consensus report from the bleeding academic research consortium.
        Circulation. 2011; 123: 2736-2747
        • Lewis B.
        Thrombocytopenia and outcome in invasive cardiology.
        J Invasive Cardiol. 2002; 14: 38B-47B